↑↓ navigate ↵ open esc close
SELL TO STATE.
Start free trial
Germany TED / Vergabe.de contract award · ocds-ted-635720-2025-3

Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wir

DAK-Gesundheit awarded a contract of undisclosed value to ROVI GmbH for Healthcare & Medical in September 2025 — one of 389 awards this buyer has made.

Healthcare & Medical
29 Sep 2025
Award date
Not disclosed
Contract value

Buying agency

DAK-Gesundheit
389 Awards
€581K Avg award

Winning supplier

ROVI GmbH
30 Awards
2 Buyers

Contract description

Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Enoxaparin (ausschließlich IFE 100 mg N2), ATC B01AB05 für die Zeit 01.04.2025 - 31.03.2027

Premium

Related awards · DAK-Gesundheit

389 awards

The buyer's full award list ranked by value, with the winning supplier, date and sector on every row — plus CSV / API export.

Tender no.SupplierAmountDateSector

Full dataset

Unlock the full data.

Subscribe to reveal every row, year-over-year trends, and CSV / API export.

Unlock full dataset →

345 more awards from this buyer · full history & CSV export

Premium

Other wins · ROVI GmbH

30 wins

The supplier's complete win history across every buyer it sells to — not just the handful shown here.

Tender no.BuyerAmountDateSector
Locked rows — unlock the full dataset below.

Premium · full dataset

See the full award context.

Competing bids, award margins and every related contract for DAK-Gesundheit and ROVI GmbH — one subscription unlocks everything.

Sign Up Free →

Free account · cancel anytime · 14-day money-back

Sign Up